RecruitingNot ApplicableNCT06327945

Transplanting Lungs From Uncontrolled Donation After Circulatory Death

Transplanting Lungs From Uncontrolled Donation After Circulatory Death: An Early Phase Clinical Trial


Sponsor

NYU Langone Health

Enrollment

24 participants

Start Date

Jan 24, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The study team developed an uncontrolled donation after circulatory death (uDCD) protocol that preserves lungs for just over 3 hours after death using positive end expiratory pressure (PEEP) and supplemental oxygen. The study will assess lung uDCD program safety by continuous review of operations/clinical records from each case activation and transplantation. Attrition outcomes include rates of initial and continued lung preservation, donation authorization, lung recovery, passing ex-vivo lung perfusion (EVLP) performance testing, and lung transplantation. Planned viability assessments also include macroscopic determination, radiology (X-ray), and fiber optic bronchoscopy before initiating EVLP. We expect \~50% of lungs assessed with EVLP will be transplanted to meet sustainability targets. Safety outcomes include the primary outcome, primary graft dysfunction (PGD) grade III at 72 hours, and secondarily survival one year after transplantation.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Patients waiting for lung transplants
  • Willing to participate in the research study

Exclusion Criteria2

  • Unable to be followed for 1 year after transplantation
  • Unable to provide written informed consent to participate in the research (or designate a surrogate)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICELung uDCD Protocol

The intervention is initiation of PEEP and supplemental oxygen, without requiring prior permission (e.g., for cases not having first person authorization for organ donation and organ donation for research), to offer lung donation opportunities for cases which would otherwise be ineligible in the U.S.


Locations(1)

NYU Langone Health

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06327945


Related Trials